Filing Flows

Filing Flows › Eton Pharmaceuticals (ETON) › Guidance history

Eton Pharmaceuticals (ETON) guidance history: what it guided and what it reported

Eton Pharmaceuticals gave guidance in 3 earnings releases on file since May 14, 2026. Its releases raised guidance 3 times and lowered it 0 times.

Revenue

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$120M (May 14, 2026) → raised $145M (Aug 13, 2026)—to be reported—

Adjusted gross margin

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY202670.0% (May 14, 2026) → reaffirmed 70.0% (Aug 13, 2026) → reaffirmed 70.0% (Nov 5, 2026)—to be reported—

Adjusted EBITDA margin

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY202635.0% (Aug 13, 2026) → reaffirmed 35.0% (Nov 5, 2026)—to be reported—

Adjusted EBITDA

The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.

PeriodGuided (and how it moved)ReportedResultvs midpoint
Q3 2026$3.0M (Aug 13, 2026)———

The latest quarter

Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%, net earnings $35.2M, operating cash flow $35.2M. The chart follows the revenue to costs, profit and cash.

Questions

Does Eton Pharmaceuticals beat its guidance?

Eton Pharmaceuticals gave guidance in 3 earnings releases on file since May 14, 2026. Its releases raised guidance 3 times and lowered it 0 times.

How often does Eton Pharmaceuticals raise guidance?

Its earnings releases raised guidance 3 times and lowered it 0 times since May 14, 2026.

Latest guidance and outlook →

Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.